Monitors and analysis of adverse event following immunization in Beihai City from 2017-2021

Abstract

Abstract: Objective To analyze the report incidence and distribution characteristics of the adverse events following immunization （AEFI） in Beihai City from 2017 to 2021. Methods Through the national AEFI information management system and Guangxi immunization planning information management system,the AEFI case information and vaccination data in Beihai City from 2017 to 2021 were collected for descriptive epidemiological analysis. Results From 2017 to 2021,232 AEFI cases of various vaccines were reported in Beihai City,and the timely reporting rate and timely investigation rate were 97.84% and 100.00%,respectively. The total reported incidence of AEFI was 5.49/100 000 doses,of which the reported incidence of general reactions was 3.43/100 000 doses and the reported incidence of abnormal reactions was 1.68/100 000 doses. The difference in the reported incidence of different types of reactions was statistically significant（P<0.05）. Among the reported AEFI cases,there were more males than females,the age was mainly <1 years old,the peak season was April to September,and the region was predominantly Haicheng District. The differences in gender,age,time of occurrence and regional distribution were statistically significant（all P<0.05）. The national immunization program vaccine with the highest reported incidence was the Diphtheria,tetanus and acellular pertussis combinedvaccine（DTaP） with a rate of 17.12/100 000 doses,and the non-national immunization program vaccine with the highest reported incidence was combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenza type b（Hib） conjugate vaccine（DTaP-IPV-Hib）,with a rate of 69.68/100 000 doses. 87.93% of AEFI cases distributed within 1 day of vaccination,and the incidence of reported abnormal reactions was higher for allergic rash,BCG lymphadenitis and angioedema. Conclusions The overall monitoring quality of AEFI in Beihai City from 2017 to 2021 meets the national monitoring requirements,but the monitoring sensitivity needs to be strengthened. The AEFI cases are mainly general reactions,and the reported incidence is within the expected range. It is recommended that the active monitoring should be strengthened in the future to further improve the quality of AEFI monitoring.

Key words: Vaccination, Adverse events following immunization, Monitoring

CLC Number:

R186

ZHOU Ling, LIU Qinghua, LIANG Jiawen, HUANG Yining. Monitors and analysis of adverse event following immunization in Beihai City from 2017-2021. [J]OCCUPATION AND HEALTH, 2023, 39(22): 3117-3122.

References

[1] 谭吉宾,郭小敏,李克莉,等.预防接种安全性及媒体宣传策略[J].中国流行病学杂志. 2016,37(3):434-438.
[2] 陈凤珍,张啟文.佛山市高明区儿童监护人疫苗接种安全认知现状及影响因素分析[J].中国医药科学,2021,11(20):166-169,200.
[3] 中华人民共和国国务院.疫苗流通和预防接种管理条例[S/OL].(2016-04-13)[2018-03-29].http://www.gov.cn/gongbao/2016-05/10/content_5070742.htm.
[4] 国务院联防联控机制疫苗接种工作协调组.新冠病毒疫苗接种技术指南(第一版)[EB/OL].(2021-03-29)[2022-03-02].http://www.gov.cn/xinwen/2021-03/29/content_5596577.htm.
[5] 中华人民共和国卫生部.全国疑似预防接种异常反应监测方案[EB/OL].(2010-06-03)[2018-04-02].http://www.sda.gov.cn/WS01/CL0056/57717.html.
[6] 杜进发,钟革,杨仁聪,等.2013年广西壮族自治区疑似预防接种异常反应监测结果分析[J].疾病监测,2015,30(4):291-295.
[7] 陆伟才,杜进发,钟革,等.2014年广西疑似预防接种异常反应监测分析[J].应用预防医学,2016,22(2):114-118.
[8] WHO and WPRO.Immunization safety surveillance:guidelines for immunization program managers on surveillance of adverse events following immunization(Second Edition)[Z].Manila:Philippines,2013.
[9] 吴瑛,李瑞平,高彩红.2010—2020年上海市奉贤区南桥镇疑似预防接种异常反应监测数据分析[J].职业与健康,2022,38(5):654-658.
[10] 周伟,吴涛,辛丹,等.2013—2019年北京市房山区疑似预防接种异常反应监测分析[J].医学动物防制,2021,37(12):1191-1194.
[11] 柯燕惠,吕轶彬,肖立楠.厦门市思明区 2015—2019 年疑似预防接种异常反应监测分析[J].海峡预防医学杂志,2021,27(1):12-14.
[12] 余娜,刘玉娜,柏晓玲,等.贵阳市≥60岁老年人新冠病毒疫苗加强免疫后AEFI主动监测分析[J].中国公共卫生,2022,38(9):1113-1117.
[13] 敬嵛淋,郑心悦,马吉胜,等.2021年阿坝州居民新冠病毒疫苗接种意愿及影响因素分析[J].预防医学情报杂志,2022,38(8):1081-1087.
[14] 张丽娜,李克莉,杜雯,等.2019年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2021,27(4):438-445.
[15] 陈凡金. 预防接种偶合症的季节性回顾与分析[J].中国热带医学,2007,7(6):988-989,995.
[16] 张国平,李克莉,杜雯,等.中国2010—2019年预防接种后心因性反应监测[J].中国疫苗和免疫,2021,27(5):589-593
[17] 陈翔,樊芸,刘鹏,等.2017—2018 年成都市龙泉驿区疑似预防接种异常反应监测分析[J].预防医学情报杂志,2020,36(2):234-239.
[18] 黄影,韦佳楠,杜进发,等.2015—2018年广西疑似预防接种异常反应监测结果分析[J].应用预防医学,2021,27(5):431-434,438.
[19] 曾泰生,林少杰,郑铁洪.2015—2017年深圳市龙岗区疑似预防接种异常反应监测[J].职业与健康,2019,35(15):2097-2101.
[20] 王四全,李克莉,许涤沙,等.中国2015—2017年无细胞百白破联合疫苗疑似预防接种异常反应监测[J].中国疫苗和免疫,2019,25(6):692-699.
[21] 马雨佳,刘艳,沈鹏,等.适龄儿童接种无细胞百白破b型流感嗜血杆菌联合疫苗疑似预防接种异常反应主动监测[J].中国疫苗和免疫,2020,26(6):679-683,687.
[22] 刘振江,吴春敏,黄家梅,等.无细胞百白破b型流感嗜血杆菌联合疫苗不同部位接种安全性及免疫原性评价[J].中国公共卫生,2022,38(2):177-180.
[23] 王建美,叶莉霞,梅秋红,等.宁波市2018—2020年适龄儿童无细胞百白破b型流感嗜血杆菌联合疫苗单独和与其他疫苗同时接种的不良反应报告发生率比较[J].中国疫苗和免疫,2021,27(6):655-658.
[24] World Health Organization.Regional Office for the Western Pacific.Immunization safety surveillance:guidelines for immunization programme managers on surveillance of adverse events following immunization.3rd ed[EB/OL].(2016)[2017-03-10].http://iris.wpro.who.int/handle/10665.1/12620.
[25] 杨旭,王旭雯.2015—2017 年无锡市含无细胞百白破成分疫苗预防接种安全性评价[J].现代预防医学,2020,47(6):1120-1123.
[26] 孙磊. 2017—2019年天津市某区含无细胞百白破联合疫苗预防接种安全性评价[J].河南预防医学杂志,2021,32(2):122-125.